HNSA — Hansa Biopharma AB Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for Hansa Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	33.9	155	134	171	222
Cost of Revenue
Gross Profit	18.5	116	71	87.8	139
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	581	743	923	809	802
Operating Profit	-547	-589	-788	-638	-580
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-548	-610	-831	-804	-527
Provision for Income Taxes
Net Income After Taxes	-548	-611	-832	-807	-529
Net Income Before Extraordinary Items
Net Income	-548	-611	-832	-807	-529
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-548	-611	-832	-807	-529
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-12.3	-13.6	-15.8	-12.8	-6.04
Dividends per Share